AZT+3TC+ABV (Trizivir) — Competitive Intelligence Brief

AZT+3TC+ABV (Trizivir) (AZT+3TC+ABV (Trizivir)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI) combination. Area: Infectious Disease / Virology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

AZT+3TC+ABV (Trizivir) (AZT+3TC+ABV (Trizivir)) — Fundacion SEIMC-GESIDA. Trizivir is a fixed-dose combination of three nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AZT+3TC+ABV (Trizivir) TARGET	AZT+3TC+ABV (Trizivir)	Fundacion SEIMC-GESIDA	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Nevirapine, FTC, and Tenofovir	Nevirapine, FTC, and Tenofovir	University of Maryland, Baltimore	marketed	Antiretroviral combination (NNRTI + NRTI + NtRI)	HIV reverse transcriptase, HIV integrase
Tenofovir + emtricitabine + lopinavir/ritonavir	Tenofovir + emtricitabine + lopinavir/ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + protease inhibitor)	HIV reverse transcriptase, HIV protease
Lopinavir/ritonavir + zidovudine + lamivudine	Lopinavir/ritonavir + zidovudine + lamivudine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Atripla (r)	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
lamivudine or entecavir	lamivudine or entecavir	Sun Yat-sen University	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI)	Hepatitis B virus reverse transcriptase; HIV reverse transcriptase
Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir	Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir	St Stephens Aids Trust	marketed	Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI)	HIV integrase (dolutegravir); HIV reverse transcriptase (efavirenz and combination); HIV entry (tenofovir/emtricitabine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) combination class)

1. Medical Research Council · 2 drugs in this class
2. Bristol-Myers Squibb · 1 drug in this class
3. Fundacion SEIMC-GESIDA · 1 drug in this class
4. GlaxoSmithKline · 1 drug in this class
5. Janssen Scientific Affairs, LLC · 1 drug in this class
6. Merck Sharp & Dohme LLC · 1 drug in this class
7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
8. Tibotec, Inc · 1 drug in this class
9. University of North Carolina, Chapel Hill · 1 drug in this class
10. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class